REG - OptiBiotix Health - SlimBiome® distribution agreement for Germany

OptiBiotix HealthAnnouncement

19/12/2019 07:05

RNS Number : 3997X
OptiBiotix Health PLC
19 December 2019
 


OptiBiotix Health plc
("OptiBiotix" or the "Company")
 
SlimBiome® distribution agreement for Germany
 
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high
cholesterol, diabetes and skincare, announces it has entered into an exclusive agreement with Draco Ingredients GmbH ("Draco") to distribute OptiBiotix's SlimBiome® proprietary weight management technology in Germany. Market exclusivity is linked to minimum order quantities in order to maximise the financial return for both parties. 
 
Draco Ingredients (www.draco-ingredients.de) is a German food ingredient company established in 2001 focusing on the distribution of mainly dairy based ingredients to a broad spectrum of customers active in segments such as dairy, sports and medical nutrition.
 
This agreement is another step in extending the geographical reach and sales of SlimBiome®. This is consistent with our strategy of increasing the number of geographies and applications SlimBiome® is used in as an ingredient. This builds revenue potential and brand recognition and reduces commercial risk.
 
Andre Wittke, General Manager of Draco Ingredients, commented: "We are delighted to have the opportunity of partnering with Optibiotix and look forward to building a presence for SlimBiome® in Germany by leveraging on the strengths of both organisations. We see SlimBiome's unique value proposition (patented solution backed by clinical and consumer studies and supported by EFSA-approved claims) as being a key driver of the sale of this functional ingredient to German customers in the near future."
 
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are pleased to announce this agreement with Draco Ingredients to service the German market. The timing of this agreement fits particularly well with our recent focus on creating the building-blocks necessary to accelerate and expand our reach to customers globally. This deal builds on the work done in 2019 to qualify multiple manufacturers of SlimBiome® in Europe and around the world (e.g Zeon: India, Agropur: USA) to de-risk our supply-chain in the case of a hard Brexit and give us access to one of Europe's largest economies."
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 
For further information, please contact:
 




OptiBiotix Health plc


www.optibiotix.com




Stephen O'Hara, Chief Executive


Contact via Walbrook below




 


 




Cairn Financial Advisers LLP (NOMAD)


Tel: 020 7213 0880




Liam Murray / Jo Turner / Ludovico Lazzaretti


 




 


 




finnCap (Broker)


Tel: 020 7220 0500




Geoff Nash / Kate Bannatyne (Corporate Finance)


 




Camille Gochez (Corporate Broking)


 




 


 




goetzpartners securities Limited


Tel: 0203 859 7725




Ulrich Kinzel 


 




 


 




Walbrook PR Ltd


Mob: 07876 741 001




Anna Dunphy


 



 
 
 



 
 
 
About OptiBiotix - www.optibiotix.com 
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 
 
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than 20 international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
 
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 
 
 
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCCKFDNFBDDOBD